Rochester, NY, December 16, 2023 –The Huntington Study Group together with its wholly-owned clinical research organization, HSG Clinical Research, Inc. (HSGCR), is pleased to announce a collaboration with Roche-Genentech to optimize our collective experiences in Huntington’s disease (HD) clinical research. Together we are working to understand the recruitment and enrollment needs of Roche’s GENERATION HD2 study. HSG is utilizing their long-standing history of expert recruitment, retention, and enrollment strategies to connect the HD community with participating sites.
Through this collaboration, and close work with HSG credentialed sites, HSG’s clinical operations services will advise Roche on the recruitment and enrollment needs of GENERATION HD2, a study being conducted by Roche-Genentech in 15 countries to evaluate the safety, biomarkers, and efficacy of tominersen compared with placebo in participants with prodromal and early manifest HD. Together with Roche, HSG will work to offer further opportunities to explore and incorporate strategies to successfully identify potential participants for the GENERATION HD2 study focused on the US sites.
Roche/Genentech Clinical Trial Lead, Peter McColgan said, “HSG’s established expertise in HD research including recruitment, enrollment, and retention were key factors in selecting them for this project. We have worked together in the past and look forward to this new endeavor that will allow us to collectively our study sites, participants, and the HD community.”
HSG and Roche hosted a GENERATION HD2 Site Investigator and Coordinator Meeting on November 3, 2023, during the HSG 2023 Annual Meeting in Phoenix, AZ. Investigators and Coordinators came together to discuss clinical trial recruitment efforts, ideas and share from HD patients to allow for their voices to be heard and address successes or barriers to recruitment.
Shari Kinel, CEO of Huntington Study Group noted, “This is a great opportunity for HSG and Roche to strengthen and grow our partnership, allowing us to collectively work toward accelerating treatments that make a difference to improve the lives of people impacted by Huntington’s disease.”